SCM
SRPT icon

Stonebridge Capital Management’s Sarepta Therapeutics SRPT Stock Holding History

Stonebridge Capital Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-2,870
Closed -$232K – 136
2018
Q1 		$232K Buy
+2,870
New +$191K 0.08% 114
2017
Q4 		– Sell
-5,835
Closed -$265K – 140
2017
Q3 		$265K Buy
+5,835
New +$233K 0.1% 114

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return

Stonebridge Capital Management's SRPT Position: Q2 2018 in Review

Stonebridge Capital Management sold out of Sarepta Therapeutics (SRPT) in Q2 2018, closing a stake of 2,870 shares — an estimated $232K sold.

Stonebridge Capital Management first reported a position in SRPT in Q3 2017 and held it in 2 quarters. The position peaked at $265K in Q3 2017. 317 funds tracked by Wall St. Rank hold SRPT as of Q2 2018.

  • Stonebridge Capital Management reported no remaining Sarepta Therapeutics position as of Q2 2018 after selling out during the quarter.
  • Stonebridge Capital Management sold 2,870 Sarepta Therapeutics shares in Q2 2018, an estimated $232K.
  • Stonebridge Capital Management first reported a position in Sarepta Therapeutics in Q3 2017 and held it in 2 quarters.
  • Stonebridge Capital Management's Sarepta Therapeutics position peaked at $265K in Q3 2017.
  • 317 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2018.

Based on Stonebridge Capital Management's 13F filing for Q2 2018, filed 6 Jul 2018.